Fulcrum Therapeutics, Inc.

FULC

US3596161097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.14 ^USD	+0.14%		+4.39%	+5.78%

Mar. 18	Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	MT
Mar. 18	Fulcrum Therapeutics, Inc. Announces Executive Changes	CI

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index

March 17, 2024

Latest news about Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	Mar. 18	MT
Fulcrum Therapeutics, Inc. Announces Executive Changes	Mar. 18	CI
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
GSK: Dr Jeannie Lee joins the Board of Directors	Feb. 29	CF
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $15 From $13, Maintains Overweight Rating	Feb. 28	MT
Transcript : Fulcrum Therapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $6 From $5, Maintains Neutral Rating	Jan. 25	MT
Transcript : Fulcrum Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer	Nov. 01	MT
Fulcrum Therapeutics, Inc. Announces Resignation of Mel Hayes as Chief Operating Officer	23-10-02	CI
Fulcrum Therapeutics Completes Patient Enrollment for Phase 3 Study of Losmapimod	23-09-07	MT
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
HC Wainwright Upgrades Fulcrum Therapeutics to Buy From Neutral, Adjusts Price Target to $14 From $5	23-08-23	MT
North American Morning Briefing : Nvidia Results -2-	23-08-23	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	23-08-22	MT
Sector Update: Health Care Stocks Lower in Afternoon Trading	23-08-22	MT
Sector Update: Health Care	23-08-22	MT
Top Midday Gainers	23-08-22	MT
Fulcrum Therapeutics Shares Soar After Stifel Upgrade	23-08-22	MT
Correction: US Equity Futures Set to Open Higher as Traders Digest Major Retailers' Earnings	23-08-22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	23-08-22	MT
Retail Earnings Weigh on Sentiment, Driving Premarket Losses for US Equity Futures	23-08-22	MT

Chart Fulcrum Therapeutics, Inc.

Duration

Period

More charts

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Companyâs clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Fulcrum Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.14 USD

Average target price

13.25 USD

Spread / Average Target

+85.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FULCRUM THERAPEUTICS, INC.	+5.78%	444M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research